CompilationAspirin
Sanofi axed two more cancer-preventing monoclonal antibodies in Phase 1
induces immune tolerance by regulating CD8+ T cell thymus development
Time of Update: 2022-05-01
with chronic infection. However, its detailed cellular and molecular mechanisms are still unclear . Recently, Yuan Zhenghong's team from the Department of Pathogenic Biology
Promoting the development of precision medicine AI-driven single-cell analysis platform receives US$73 million
Time of Update: 2022-04-30
The company's technology platform combines AI, proprietary microfluidics, high-resolution optics, and a growing cell atlas, which contains more than 1 billion visual feature-based images to analyze and classify cells, according to the press release .
FDA issues draft guidance on development considerations for CAR-T cell therapy
Time of Update: 2022-04-30
In the draft guidance, the FDA provides specific recommendations for CAR-T cells on chemistry, manufacturing and control (CMC), pharmacology and toxicology, and clinical study design .
treatment of extensive-stage small cell lung cancer ELCC 2022
Time of Update: 2022-04-27
, and at least one measurable lesion . All patients received 4-6 cycles of durvalumab combined with EP first-line therapy (durvalumab 1500 mg, d1; cisplatin or carboplatin, d1; etoposide
On the Cell: Wei Wensheng's team develops a circular RNA vaccine that is effective against Delta and Omicron
Time of Update: 2022-04-27
Domain (RBD) circular RNA vaccine (circRNA-RBD) was able to elicit potent neutralizing antibodies and T cell responses, resulting in effective protection against Delta and Omicron mutants .
Lancet: K drug adjuvant treatment of high-risk stage II melanoma significantly improves RFS
Time of Update: 2022-04-27
interim analysis of KEYNOTE-716 evaluating pembrolizumab as adjuvant therapy in patients with completely resected high-risk stage II melanoma . Studies have shown that adjuvant
Guangzhou Health Center establishes and analyzes human 8-cell stage embryo-like cells in vitro
Time of Update: 2022-04-26
modeling . The scientific research team will further establish a high-efficiency and high-purity human 8CLC totipotent cell production platform, and use the totipotent cells to prepare functional
NBT Dai Qionghai and others developed an artificial intelligence method for fusion analysis of cell microscopic images and genetic data—MUSE
Time of Update: 2022-04-25
> Based on the research group's accumulation in optical microscopy (Cell 2021, Nature Photonics 2019, 2020), single-cell gene analysis technology (Nature Methods 2019) and cross-application of artificial intelligence (Nature
CAR-T cell therapy Yescarta wins FDA approval for early-stage lymphoma treatment
Time of Update: 2022-04-24
lymphomaGilead Sciences announced today that the FDA has expanded the approval of Yescarta (axicabtagene ciloleucel) to include patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who have relapsed within 12 months of first-line chemoimmunotherapy .
BMC Cancer: Unresectable stage III non-small cell lung cancer (NSCLC) with platinum-based
Time of Update: 2022-04-24
Therefore, a team from Japan conducted a related study to evaluate the efficacy of platinum-based chemotherapy as second-line therapy in patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy .
Front Oncol: Systematic lymphadenectomy improves patient outcomes in patients with early-stage endometrial clear cell carcinoma
Time of Update: 2022-04-23
Studies have shown that patients with early-stage endometrial clear cell carcinoma who underwent systematic lymphadenectomy had better long-term survival than those who did not .
Published data from Merck's pembrolizumab adjuvant treatment in patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Time of Update: 2022-04-23
>Studies have shown that even after complete tumor resection, patients with non-small cell lung cancer still have the risk of postoperative recurrence, metastasis and second primary lung cancer, and more than 50% of tumor recurrence or metastasis occurred
Announcement of data from a study of pembrolizumab in adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Time of Update: 2022-04-23
>even after complete tumor resection, patients with non-small cell lung cancer still have the risk of postoperative recurrence, metastasis and second primary lung cancer. More than 50%
Phase III study of tiragolumab combined with atezolizumab in extensive-stage small cell lung cancer failed (SKYSCRAPER-02 study)
Time of Update: 2022-04-23
The SKYSCRAPER-02 study will explore the efficacy of a new combination therapy regimen, Tiragolumab + Atezolizumab + chemotherapy, in extensive-stage small cell lung cancer .
Cell Wei Wensheng's research group reported the circular RNA technology platform and the new anti-new coronavirus vaccine developed accordingly
Time of Update: 2022-04-18
of neutralizing antibodies in the body, which can more effectively fight against virus mutation and reduce the potential side effects of antibody-dependent enhancement (ADE) of the vaccine; 3) The ratio of IgG2/IgG1 induced by circRNA vaccine is higher
